Roivant Sciences Ltd. (ROIV)
After hours:
| Previous close | 4.4900 |
| Open | 4.4400 |
| Bid | 4.1300 x 800 |
| Ask | 4.1500 x 1100 |
| Day's range | 4.0600 - 4.4500 |
| 52-week range | 2.5200 - 16.7600 |
| Volume | |
| Avg. volume | 828,990 |
| Market cap | 2.852B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.5170 |
| Earnings date | 28 Jun 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.57 |
- Simply Wall St.
Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's been a good week for Roivant Sciences Ltd. ( NASDAQ:ROIV ) shareholders, because the company has just released its...
- GlobeNewswire
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical psoriasis prescriptions in the USEnrollment in the VTAMA registrational trials for atopic dermati
- GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm
